Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function

• Main Authors: Wei Yin (Author), Pranab Mitra (Author), Veronique Copalu (Author), Thomas C. Marbury (Author), Juan Carlos Rondon (Author), Eric J. Lawitz (Author), Valerie Lloyd (Author), Mike Baratta (Author), Mahnaz Asgharnejad (Author), Tom Hui (Author), Yasir Khan (Author)
• Format: Book
• Published: Wiley, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract This phase 1, open‐label, three‐arm study (NCT05098054) compared the pharmacokinetics and safety of soticlestat (TAK‐935) in participants with hepatic impairment. Participants aged ≥18 to <75 years had moderate (Child‐Pugh B) or mild (Child‐Pugh A) hepatic impairment or normal hepatic fu...